Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial.

PLoS One · 2013 · PMC3720651 · PMID 23935969

Europe PMC DOI

hedged sentence

0.0720

closest p · 1.4× alpha

0.0720

boldest claim

The sentences

did not reach statistical significancep = 0.072so close (0.05 < p ≤ 0.1)

By contrast, high TUBB3 transcript levels (cut-off at 75% of RQ values) were expressed in tumors from patients with unfavorable outcome, although these results did not reach statistical significance (p = 0.072).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.